Is TB-500 Legal in Louisiana?

What Exactly Is TB-500?

TB-500 is a synthetic peptide derived from the C-terminal region (amino acids 17 through 23) of thymosin beta-4, a naturally occurring 43-amino-acid protein found in virtually every cell in the human body. The full protein thymosin beta-4 was first isolated from thymus tissue in the 1960s, but the short peptide fragment marketed as TB-500 is the portion researchers identified as most bioactive for actin-sequestration, cell migration, and downregulation of inflammatory cytokines.

Mechanism of Action

Thymosin beta-4 binds G-actin monomers at a 1:1 ratio, preventing their polymerization and thereby controlling the pool of free actin available for cytoskeletal remodeling. This mechanism supports keratinocyte and endothelial cell migration, which is relevant to wound closure and angiogenesis. In animal studies, subcutaneous thymosin beta-4 accelerated full-thickness dermal wound closure in rats by approximately 42% compared with saline controls, according to a 2010 study published in the Annals of the New York Academy of Sciences ([1]).

Why It Is Called "TB-500"

The "TB" designation simply references thymosin beta. The "500" is a vendor-assigned catalog label, not an official pharmacological designation. The FDA has never assigned TB-500 an NDA (New Drug Application) number or an IND (Investigational New Drug) approval for commercial use in humans.

Current Clinical Research Status

RegeneRx Biopharmaceuticals conducted Phase II trials of full-length thymosin beta-4 (RGN-352) for cardiac repair after acute myocardial infarction and for neurotrophic keratitis. Those trials used the full 43-amino-acid protein, not the shorter TB-500 fragment. No Phase III trial of either form has reached completion with an FDA marketing approval outcome. The ClinicalTrials.gov registry (NCT01311518) lists one completed cardiac trial; no randomized controlled trial has been registered specifically for the TB-500 fragment in humans as of this writing ([2]).

Federal Legal Framework for TB-500

The federal government, through the FDA, sets the baseline rules that every state, including Louisiana, must operate within. Understanding these rules is essential before examining anything at the state level.

FDA Approval and the Adulteration Prohibition

TB-500 is not an FDA-approved drug. Under 21 U.S.C. § 331, introducing an unapproved new drug into interstate commerce is prohibited. Any TB-500 sold by an online vendor as a finished product intended for human use violates this provision regardless of where the buyer lives.

The FDA's website classifies peptides sold online as "research chemicals" when vendors label them "not for human use" as a legal disclaimer. In practice, the FDA has sent Warning Letters to multiple peptide vendors for exactly this conduct, citing the misbranding and adulteration provisions of the Federal Food, Drug, and Cosmetic Act ([3]).

The 503A Compounding Pharmacy Pathway

Section 503A of the FD&C Act permits state-licensed compounding pharmacies to prepare customized drugs for individual patients when a valid prescription exists and the drug is not a copy of a commercially available product. Critically, 503A pharmacies may only compound from bulk active pharmaceutical ingredients (APIs) that appear on the FDA's 503A Bulks List (21 C.F.R. § 216.24) or that are components of FDA-approved drugs.

Thymosin beta-4 does not currently appear on the FDA's 503A Bulks List. The FDA's Pharmacy Compounding Advisory Committee reviewed thymosin beta-4 and determined it lacks sufficient evidence of clinical need to justify inclusion. This means a standard Louisiana compounding pharmacy operating under 503A cannot legally prepare TB-500 for individual patients without risking federal enforcement action ([4]).

The 503B Outsourcing Facility Pathway

Section 503B of the FD&C Act created a category of FDA-registered "outsourcing facilities" that may produce compounded drugs in larger batches without patient-specific prescriptions, provided those drugs appear on the FDA's 503B Bulks List or qualify under other criteria. Thymosin beta-4 and its analogues are not listed on the current 503B Bulks List either.

A 503B facility could theoretically petition the FDA to add thymosin beta-4 to the list by submitting a nomination with clinical need documentation. As of 2025, no successful nomination has resulted in TB-500 or thymosin beta-4 appearing on the 503B Bulks List ([5]).

DEA Scheduling Status

TB-500 is not listed in any schedule under the Controlled Substances Act. Its absence from DEA scheduling means simple possession for personal use does not carry the criminal penalties that attach to Schedule I or II substances. However, the absence of DEA scheduling does not make TB-500 legal to sell, distribute, or administer as a drug. Federal adulteration and misbranding law operates independently of the CSA.

Louisiana State Legal Framework

Louisiana does not have a separate state statute that specifically names TB-500, thymosin beta-4, or synthetic peptide analogues as controlled dangerous substances or prohibited substances. The Louisiana Revised Statutes Title 40 (Health and Safety) governs controlled dangerous substances, and TB-500 does not appear in any schedule thereunder.

Louisiana Board of Pharmacy Rules

The Louisiana Board of Pharmacy (LABP) licenses and regulates all pharmacies operating in the state, including compounding pharmacies. The LABP's compounding regulations align closely with USP Chapter 795 (non-sterile) and USP Chapter 797 (sterile preparations). These chapters govern quality standards but do not independently authorize compounding from APIs that are barred at the federal level.

A Louisiana-licensed 503A pharmacy that compounds TB-500 from bulk thymosin beta-4 would be compounding from an API not on the FDA 503A Bulks List. That conduct would expose the pharmacy to federal enforcement even if the LABP took no separate disciplinary action. The LABP has not issued a specific advisory statement on TB-500 as of this writing.

Louisiana Medical Practice Act and Physician Authority

Under Louisiana Revised Statutes § 37:1271, a licensed Louisiana physician has broad authority to prescribe any substance for a legitimate medical purpose within the standard of care. Prescribing a non-controlled, non-approved substance is not per se illegal in Louisiana. Physician discipline could arise, however, if the Medical Board found the prescription fell outside accepted medical standards or lacked documented clinical rationale.

The Louisiana State Board of Medical Examiners (LSBME) has not published specific guidance on peptide prescribing as of 2025. A physician prescribing TB-500 for a patient would need to rely on informed consent documentation, a well-documented clinical chart, and a pharmacy capable of legally filling the prescription. Given the 503A Bulks List restriction, finding a compliant filling pharmacy is the practical barrier, not Louisiana physician licensing law itself.

Personal Possession

Louisiana has no statute that criminalizes personal possession of TB-500 in the way that possession of a Schedule I drug is criminalized. A Louisiana resident who receives TB-500 from an out-of-state vendor may not face state criminal liability for mere possession, but the federal adulteration and misbranding framework remains applicable to the seller, and the product itself would be considered adulterated or misbranded under federal law.

HealthRX Legal Pathway Framework: TB-500 in Louisiana

| Pathway | Legally Permissible in Louisiana? | Key Barrier | |---|---|---| | Purchase from online "research chemical" vendor | No (federal adulteration/misbranding) | 21 U.S.C. § 331 | | 503A compounding pharmacy (patient-specific Rx) | Not currently supported | Thymosin beta-4 absent from FDA 503A Bulks List | | 503B outsourcing facility (physician order) | Not currently supported | Thymosin beta-4 absent from FDA 503B Bulks List | | FDA-approved finished drug | No | No approved product exists | | Licensed research institution (IND or exempt protocol) | Yes, with proper oversight | Requires IRB approval or IND filing | | Veterinary use | Separate regulatory path; not addressed here | USDA/FDA veterinary rules apply |

How Physicians and Patients Manage Access Today

Given the compounding restrictions, a small number of patients and providers have pursued TB-500 access through channels that exist in regulatory gray areas. Understanding each channel's risk profile matters.

The "Research Use Only" Vendor Channel

Many vendors sell TB-500 online labeled "research use only" or "not for human use." This label does not create legal protection for the buyer or seller when the product is destined for human administration. The FDA has issued Warning Letters to peptide vendors (including letters cited in the FDA's 2022 constituent update on compounded peptides) stating that labeling a product "for research" does not exempt it from the FD&C Act when the intended use is human consumption ([6]).

Patients who order TB-500 from these vendors receive a product with no guaranteed sterility, no verified API concentration, and no chain of custody documentation. Independent laboratory testing of peptides purchased online has found concentration variances of 20% to 80% from labeled amounts, according to published analyses of gray-market peptide samples ([7]).

Pursuing an IND for Legitimate Research

A Louisiana-based physician or research institution can legally administer TB-500 to human subjects by filing an Investigational New Drug (IND) application with the FDA under 21 C.F.R. § 312. This pathway requires an IRB-approved protocol, GMP-grade API, safety monitoring, and adverse event reporting. Most private clinics cannot meet these requirements without institutional infrastructure, but academic medical centers in Louisiana (such as LSU Health or Tulane University School of Medicine) could theoretically support such an investigation.

Watching the Bulks List

The most likely route to legitimate widespread clinical access is a successful FDA nomination of thymosin beta-4 to the 503A or 503B Bulks List. The FDA accepts nominations through its docket system (regulations.gov). Physicians, patients, and compounding pharmacy groups have submitted nominations for various peptides. The FDA evaluates each nomination based on clinical need, safety data, and whether adequate alternatives exist. If thymosin beta-4 were added to the 503B Bulks List, outsourcing facilities nationwide, including those servicing Louisiana prescribers, could legally produce it under GMP conditions ([5]).

What the Existing Science Says (and Does Not Say)

No randomized, placebo-controlled trial has demonstrated statistically significant clinical benefit of the TB-500 fragment specifically in humans. The available human data on thymosin beta-4 come from trials of the full-length protein in ophthalmology and cardiology, where results have been modest.

Animal and In Vitro Data

A 2010 publication in the Annals of the New York Academy of Sciences reported that thymosin beta-4 accelerated dermal wound healing and reduced inflammatory markers in rodent models ([1]). A 2011 study in the Journal of Molecular Medicine found that thymosin beta-4 promoted cardiac progenitor cell migration after myocardial infarction in mice ([8]).

Human Trial Data

The RegeneRx Phase II cardiac trial (NCT01311518, N=72) tested intravenous thymosin beta-4 after ST-elevation myocardial infarction. The primary endpoint of left ventricular ejection fraction improvement at 6 months did not reach statistical significance (P = 0.23) ([2]). A separate Phase II trial for neurotrophic keratitis (RGN-259) showed a statistically significant improvement in corneal staining at Day 28 compared with vehicle (P<0.05), but no approved ophthalmic product for TB-500 exists as of 2025 ([9]).

The gap between animal findings and human trial results is meaningful. Patients and providers should weigh the limited human efficacy data alongside the legal and safety considerations.

Safety Profile

No serious adverse events were attributed to thymosin beta-4 at clinical doses in the Phase II cardiac trial. The peptide is endogenous, which suggests a favorable tolerability profile. At the same time, gray-market products carry contamination risks that clinical trial formulations do not. The absence of reported harm in regulated trials does not extend to unsterile, unverified gray-market vials.

Direct Guidance for Louisiana Patients

Louisiana residents asking about TB-500 should keep the following points in mind before making any decisions.

Step 1: Consult a Licensed Louisiana Physician

Any legal pathway to TB-500 begins with a physician licensed by the LSBME. A physician can document clinical rationale, explore whether any compliant compounding options emerge as the regulatory environment evolves, and provide informed consent counseling.

Step 2: Do Not Order From Gray-Market Vendors

Purchasing TB-500 from unregulated online vendors exposes patients to products with unknown purity, unknown sterility, and unknown concentration. The federal prohibition on distributing unapproved drugs in interstate commerce applies to those vendors; the patient's legal risk is lower than the vendor's, but the safety risk is entirely the patient's.

Step 3: Ask the Prescribing Physician About IND Options

If you are a Louisiana patient with a documented clinical condition for which thymosin beta-4 has shown early-stage promise (such as refractory wound healing or specific cardiac conditions), your physician may explore whether an IND application is feasible through an affiliated research institution.

Step 4: Monitor FDA Bulks List Updates

The FDA updates its 503A and 503B Bulks Lists periodically. If thymosin beta-4 is eventually nominated and approved for either list, the legal field will change substantially. Signing up for FDA constituent updates at fda.gov ensures you receive timely notification ([3]).

As of January 2025, the FDA's Bulks List for 503A compounding does not include thymosin beta-4 or TB-500, meaning no compliant 503A pathway currently exists for Louisiana patients.